Publications by authors named "S L Hammond"
Article Synopsis
- Fine particulate matter (PM) exposure can lead to immune system issues through epigenetic changes, potentially impacting pregnancy outcomes.
- The study used advanced profiling techniques to link PM exposure with altered immune responses and specific histone modifications in immune cells of both pregnant and nonpregnant women.
- Findings suggest that high maternal PM exposure correlates with lower IL-27 levels in newborns and affects the inflammatory response in pregnant women, indicating possible pathways for complications during pregnancy.
Image-Guided Radiation Therapy Is Equally Effective for Basal and Squamous Cell Carcinoma.
Dermatopathology (Basel)
November 2024
Non-melanoma skin cancers (NMSCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are highly prevalent and a significant cause of morbidity. Image-guided superficial radiation therapy (IGSRT) uses integrated high-resolution dermal ultrasound to improve lesion visualization, but it is unknown whether efficacy varies by histology. This large retrospective cohort study was conducted to determine the effect of tumor histology on freedom from recurrence in 20,069 biopsy-proven NMSC lesions treated with IGSRT, including 9928 BCCs (49.
View Article and Find Full Text PDFArticle Synopsis
- Nematodes, like Caenorhabditis elegans, experience population cycles and have a survival strategy called diapause, which allows them to produce stress-resistant larvae during tough conditions like starvation.
- The gut microbiome of mixing populations of C. elegans is well-studied, but the microbiome associated with dauer larvae remains largely unexplored, making it interesting for understanding how microbes are passed between nematode generations.
- Research findings show that these dauers typically lack gut bacteria, indicating that the relationship between the host and its microbiome may not be stable over generations, potentially hindering coevolution of the two.
Background: HER2-targeted therapies have significantly improved outcomes for patients with HER2-positive breast cancer (BC), which represents 15% to 20% of all BC cases. HER2 status is assessed via immunohistochemistry (IHC) and/or in situ hybridization (ISH), dividing BCs into five groups (G1-G5).
Patients And Methods: In a study of 2,702 primary BC cases, comprising 12.